HIGHLIGHTS
- who: Anchuan Li from the Department of Radiation Oncology, Fujian Medical University Union Hospital, Xinquan Road, Fuzhou, China have published the research: Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study, in the Journal: (JOURNAL)
- what: This study aimed to compare the survival outcomes acute toxicities and surgical complications in LARC patients who received preoperative chemoradiotherapy with triweekly oxaliplatin and capecitabine (triweekly XELOX) or capecitabine. In the present study, compared to the capecitabine regimen, intensified chemotherapy with triweekly XELOX offered no statistically significant survival . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.